Rathbones Group PLC Cuts Stake in Johnson & Johnson $JNJ

Rathbones Group PLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 762,771 shares of the company’s stock after selling 39,108 shares during the period. Rathbones Group PLC’s holdings in Johnson & Johnson were worth $157,855,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Cresta Advisors Ltd. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $26,000. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson during the 3rd quarter worth approximately $26,000. DecisionPoint Financial LLC increased its stake in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after buying an additional 75 shares during the period. Bay Harbor Wealth Management LLC increased its stake in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after buying an additional 49 shares during the period. Finally, Family CFO Inc purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $31,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research report on Wednesday, April 15th. Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, April 15th. Rothschild & Co Redburn increased their price objective on shares of Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a research report on Thursday, February 19th. Finally, Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, April 24th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts are pointing to J&J’s expanding pipeline, new drug approvals, and stronger cancer-drug sales as drivers of longer-term growth. J&J’s Pipeline Progress & New Drugs Promise Stronger Long-Term Growth
• Positive Sentiment: New product momentum, including the global launch of the Shockwave C2 Aero coronary IVL catheter and encouraging clinical data in inflammatory bowel disease, is reinforcing optimism around JNJ’s medtech and immunology businesses. How Investors May Respond To Johnson & Johnson (JNJ) Advancing Immunology, Cardiology And Surgical Robotics Platforms
• Positive Sentiment: J&J continues to be highlighted as a high-quality dividend stock, with articles emphasizing its defensive profile and reliability for income-focused investors. These 3 Dividend Stocks Are as Close to a Sure Thing as Investing Gets
• Neutral Sentiment: Several roundup and conference articles kept JNJ in the spotlight, but they mostly reiterated existing themes rather than delivering a major new catalyst. Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson…

Johnson & Johnson Trading Down 0.3%

Shares of Johnson & Johnson stock opened at $229.22 on Thursday. The company has a fifty day simple moving average of $234.43 and a 200-day simple moving average of $222.90. Johnson & Johnson has a 12-month low of $149.04 and a 12-month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a market cap of $551.78 billion, a price-to-earnings ratio of 26.50, a PEG ratio of 2.25 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same quarter in the prior year, the business posted $2.77 EPS. The company’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio (DPR) is currently 60.12%.

Insider Activity

In other news, EVP Timothy Schmid sold 1,322 shares of the company’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.